BAYER AG NA O.N.
Commented by Armin Schulz on January 3rd, 2022 | 08:59 CET
Bayer, Memiontec, Deutsche Telekom - With blue chips through inflation
When inflation rates started to rise in the USA and Germany, all sides initially said this phenomenon was temporary. In the meantime, it has become clear that the experts were wrong. Inflation has come to stay and brings inflation rates we have not seen for decades. In November, it was 5.2% in Germany. Typically, it would be the ECB's job to control inflation, but its hands are tied because of the interest rate problem. That leaves investors with the question of how best to protect their money. One option is to look at blue chips, three of which we will examine in more detail today.
Read
Commented by André Will-Laudien on December 30th, 2021 | 11:53 CET
Royal Dutch, Saturn Oil + Gas, Bayer: The oil price and the pandemic in 2022
COVID-19 is a black swan for the economy, but does the pandemic favor lower or higher oil prices? Not an easy determination because, for one thing, the measures to contain the pandemic significantly lower economic activity. Production delays and supply chain failures occur, so oil demand should fall there. On the other hand, a shortage of inputs and constraints in logistics lead to higher delivery and waiting times, thus creating some hoarding pressure, which increases demand for the black gold. Due to the shortness of history, the actual connection is also little researched, i.e. how it really is could remain hidden from us for some time. Who benefits from the current cycle of price increases?
Read
Commented by Carsten Mainitz on December 28th, 2021 | 11:26 CET
Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!
The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.
Read
Commented by Stefan Feulner on December 23rd, 2021 | 11:15 CET
Novavax, Sativa Wellness Group, Bayer - The next wave ignites
There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.
Read
Commented by Stefan Feulner on December 21st, 2021 | 13:03 CET
BioNTech, Memiontec, Bayer - Catastrophic conditions
There is no question that the Corona pandemic must be fought by all means. Nevertheless, apart from the virus and the question of vaccination, testing and boosters, there are far worse problems on our planet. For example, did you know that in the top daily news, it is reported that some 2.2 billion people have no sustainable, safe and readily available access to drinking water? Or that 361,000 children under the age of five die each year from diarrheal diseases caused by dirty water and contaminated food? The issue of water will be increasingly prominent in the headlines over the next few years. You can already invest in tomorrow's winners.
Read
Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET
BioNTech, Bayer, Ayurcann: From vaccination records to cannabis
The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.
Read
Commented by Stefan Feulner on December 10th, 2021 | 13:54 CET
Bayer, Almonty Industries, JinkoSolar - Still considerable room for improvement
Inflation is growing relentlessly. In November, Germany's barometer for price increases climbed to 5.2%; a level last reached 29 years ago. Rising energy prices and exploding commodity prices are found to be the culprits here. Given the energy turnaround, the materials required for this, such as lithium, copper and cobalt, are in fact close to their highs. However, tungsten, which will be essential for electromobility in the future, still has some catching-up potential.
Read
Commented by Stefan Feulner on December 2nd, 2021 | 11:02 CET
Bayer, Ayurcann, JinkoSolar - Excellent prospects
"Release the hemp!" cult presenter Stefan Raab called for the legalization of cannabis years ago in a song he produced himself. But not Jamaica, but the traffic light coalition with SPD, FDP and the Greens caused jubilation in the various communities. The release of the drug opens up great opportunities for young companies as well as investors. In contrast to Germany, other countries have already made more progress. Currently, the cannabis sector is in correction mode on the stock market, but the long-term prospects are excellent.
Read
Commented by Armin Schulz on November 29th, 2021 | 11:36 CET
MorphoSys, Osino Resources, Bayer - Profits through takeovers
The world's most expensive takeover occurred in Germany when the Vodafone Group acquired the Mannesmann Group for EUR 190 billion in 2000. Initially, Vodafone offered only EUR 100 billion. When a company wants to take over a listed company, it must make a public offer to shareholders. At this point, the buying party is usually already the major shareholder in the takeover target. As a rule, these offers are significantly higher than the current share price in order to make the deal palatable to the shareholders. Payment is made in cash, in shares of the acquiring Company or with a mix of both. Today, we look at three companies that are the subject of takeover rumors.
Read
Commented by Fabian Lorenz on November 11th, 2021 | 13:02 CET
Bayer, TUI, Sativa Wellness: Figures move share prices
The reporting season is drawing to a close. Overall, most companies have been convincing, and the stock markets have been very friendly in recent weeks. Bayer published positive quarterly figures, raised its forecast for the full year and thus convinced the analysts from DZ Bank. Sativa Wellness benefits from the boom around cannabis and CBD. The still-new boom is growing strongly and is already in the black. At TUI, the operating figures play less of a role. The development of the Corona figures and, thus, possible travel restrictions in the coming winter are more critical. Read more about all three shares here.
Read